Sino Biopharmaceuticals announced that Sirolimus Tablets (trademark name: Qingweishi) developed by it have received marketing approval from the National Medical Products Administration, which is the first product, since China implemented the early resolution mechanism for drug patent disputes (drug patent linkage system), to obtain a 12-month market exclusivity period due to "the first generic approval plus the first successful patent challenge".

Sirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin), it can exert anti-tumor effects by interfering with the growth, differentiation, and metabolism of cancer cells. This drug has shown positive effects in the field of tumor treatment, with definite therapeutic effects on a variety of malignant tumors, fully revealing its clinical value.

Sirolimus is considered to have a great effect on patients who have drug resistance to VEGF (vascular endothelial growth factor) targeted therapy, bringing new hope to many renal cancer patients. In 2019, the global sales of Sirolimus exceeded US$2 billion.

From Tencent.com

January 3rd, 2024